Metastatic Angiosarcomas (mas): Identification of Treatments That Significantly Improve the Outcome.

10085 Background: AS represent about 1% of all soft tissue sarcomas. Few literature data are available and the impact role of the different treatments is debated. METHODS We have conducted a retrospective analysis of 149 pts treated in 14 GSF/GETO centers between August 1996 and December 2009. Prognostic factors (PF) have been identified using Log-rank test and Cox model. After adjustment to independent PF, we have estimated the impact of treatments using Cox Model. RESULTS The study population consisted of 82 (55%) women and 67 (45%) men, the median age was 60 (range, 8-92). The main primaries were soft tissue (35 pts, 23%), breast (29 pts, 19%), skin/scalp (26 pts, 7%), liver (11 pts, 7%) and heart (9 pts, 6%). 7 patients presented underlying genetic disorders. Thirty one (21%) AS arose in irradiated fields. Performance status was 0 or 1 in 75 cases (63%). 58 AS (62%) were grade 3 tumours. 86 pts (62%) presented synchronous metastasis. The main metastatic sites were lung (70, 48%), bone (38, 26%) and liver (46, 31%). The treatment consisted of weekly paclitaxel (47, 31%), doxorubicin-based regimen (69, 47%), other chemotherapy regimens (13, 8%) and surgery of metastatasis (8, 5%). 13 pts (8%) were treated with exclusive palliative care. The median follow-up and overall survival (OS) were 9 and 11 months. Under univariate analysis, the potential PF: presence of bone metastasis (p=0.0107), presence of other metastasis (p=0.0327), performance status ≥2 (p<0.0001), low level of hemoglobin (p=0.006), low level of albumin (p=0.006) and increasing in LDH level (p<0.0001). The Cox model analysis retained only one independent PF: PS ≥2 (Hazard Ratio=2.49, p<0.0001). After adjustment to PS and compared to pts treated with exclusive palliative care, the following treatments were associated with better OS: doxorubicin-containing regimens (HR=0.38, p=0.0165), weekly-paclitaxel (HR=0.36, p=0.0146) and metastasectomy (HR=0.09, p=0.0221). CONCLUSIONS Doxorubicin-based regimens, weekly paclitaxel and metastasectomy are associated with better outcome in pts with mAS. We plan to extend this database for identifying the patients benefiting from these different treatments.